As of 2026-04-06, the Intrinsic Value of Dongkook Pharmaceutical Co Ltd (086450.KQ) is 31,817.62 KRW. This 086450.KQ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 27,400.00 KRW, the upside of Dongkook Pharmaceutical Co Ltd is 16.10%.
The range of the Intrinsic Value is 21,002.57 - 68,513.47 KRW
Based on its market price of 27,400.00 KRW and our intrinsic valuation, Dongkook Pharmaceutical Co Ltd (086450.KQ) is undervalued by 16.10%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 21,002.57 - 68,513.47 | 31,817.62 | 16.1% |
| DCF (Growth 10y) | 28,965.21 - 89,784.76 | 42,865.46 | 56.4% |
| DCF (EBITDA 5y) | 28,095.23 - 44,189.45 | 30,583.15 | 11.6% |
| DCF (EBITDA 10y) | 33,454.83 - 53,164.39 | 37,197.45 | 35.8% |
| Fair Value | 9,059.95 - 9,059.95 | 9,059.95 | -66.93% |
| P/E | 19,497.01 - 26,475.39 | 22,522.62 | -17.8% |
| EV/EBITDA | 24,207.68 - 38,884.14 | 26,153.35 | -4.5% |
| EPV | 15,496.36 - 19,980.12 | 17,738.25 | -35.3% |
| DDM - Stable | 23,953.29 - 97,453.32 | 60,703.25 | 121.5% |
| DDM - Multi | 36,909.52 - 114,033.84 | 55,442.19 | 102.3% |
| Market Cap (mil) | 919,381.00 |
| Beta | 0.24 |
| Outstanding shares (mil) | 33.55 |
| Enterprise Value (mil) | 942,814.60 |
| Market risk premium | 5.82% |
| Cost of Equity | 6.48% |
| Cost of Debt | 4.25% |
| WACC | 6.22% |